HLB’s U.S. affiliate, Verismo Therapeutics and GC Cell’s U.S. affiliate, Artiva Biotherapeutics announced this week that they obtained phase 1 IND approval from the FDA for their respective next-generation chimeric antigen receptor (CAR-T) treatments.
Please refer to the following website for further details: